U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06884384) titled 'DOAC Versus VKA in Patients with Non-high-risk APS : Prospective Cohort Study' on March 13.
Brief Summary: Antiphospholipid syndrome (APS) is a thrombotic disease requiring prolonged anticoagulation. Direct oral anticoagulants (DOACs) are indicated as 1st-line therapy in venous thrombosis, compared with VKAs, due to their easier handling and lower bleeding risk for equivalent efficacy. In APS, VKAs are still the reference treatment. However, DOACs are generally introduced in the acute phase of venous, before the diagnosis of APS. VKA have the disadvantage of numerous food and drug interactions, and therefore require close monitorin...